
Ambrisan5 mg
Square Pharmaceuticals PLC.
Ambrisentan is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to improve exercise capacity and delay clinical worsening.
Ambrisentan is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to improve exercise capacity and delay clinical worsening. Indications below are classified by strength of evidence.
Dosage of Ambrisentan should be individualized and initiated only by physicians experienced in the management of pulmonary arterial hypertension.
| Indication | Population | Recommended Dose |
|---|---|---|
| Pulmonary arterial hypertension (monotherapy or in combination with a PDE5 inhibitor) | Adults | Initiate at 5 mg orally once daily; may be increased to 10 mg once daily if the lower dose is tolerated |
| Pulmonary arterial hypertension | Pediatric patients | Safety and efficacy not established; not recommended |
| Concomitant cyclosporine use | Adults | Limit Ambrisentan to 5 mg once daily |
Not recommended in moderate-to-severe hepatic impairment or with clinically significant elevations in liver aminotransferases; use with caution and close monitoring in mild hepatic impairment.
No dose adjustment is generally required in mild-to-moderate renal impairment; data in severe renal impairment are limited, so use with caution.
Side effects reported with Ambrisentan:
Ambrisentan is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.